News for Zenith Capital Corp. (ZHCLF)

Seven NCI sponsored trials will evaluate safety and efficacy of its BET inhibitor (BETi) ZEN-3694 in combination with several targeted agents and/or…

National Cancer Institute Sponsored Phase 1/1b clinical study to test combination of epigenetic and immune-oncology therapies in solid tumors and ovarian cancer

Zenith and Newsoara Biopharma Announce Expanded Licensing and Investment GlobeNewswire November 15, 2021 CALGARY, Alberta, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zenith Capital Corp. (“Zenith” or the “Company”) announced today that Zenith Epigenetics Ltd. (“Zenith Epigenetics”), a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara Biopharma Co.,...